Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam for anxiety reduction in STEMI patients undergoing primary PCI
IRCT20201102049232N3Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lorazepam in anxiety disorder (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoints: Anxiety level, Procedure time and 4 more. Started Jan 2023; status: completed.
02
Drugs
lorazepam
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on IRCT20201102049232N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201102049232N3.